EKOS introduces new endovascular system with rapid pulse modulation
EKOS has launched its EkoSonic endovascular system (ES) with rapid pulse modulation for the dissolution of vascular blood clots.
EkoSonic ES can deliver microsonic energy and thrombolytic drugs simultaneously to remove clots by accelerating dissolution, according to the company.
The EkoSonic ES received FDA clearance in late June.
EKOS said its system consists of a disposable infusion catheter with removable ultrasound core and an instrument that generates and controls the delivery of energy to the catheter. The infusion catheter contains multiple side holes distributed over the length of the treatment zone. The ultrasound core contains up to 30 ultrasound elements, evenly spaced over the treatment zone. Thermal sensors in the treatment zone monitor catheter temperature.
The EkoSonic System is intended for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature, according to the Bothell, Wash.-based company.
“Unlike mechanical devices, EKOS technology does not fracture the thrombus or damage red blood cells. Faster clot dissolution means a lower lytic drug dosage, resulting in fewer complications,” said Robert Hubert, EKOS president and CEO.
EkoSonic ES can deliver microsonic energy and thrombolytic drugs simultaneously to remove clots by accelerating dissolution, according to the company.
The EkoSonic ES received FDA clearance in late June.
EKOS said its system consists of a disposable infusion catheter with removable ultrasound core and an instrument that generates and controls the delivery of energy to the catheter. The infusion catheter contains multiple side holes distributed over the length of the treatment zone. The ultrasound core contains up to 30 ultrasound elements, evenly spaced over the treatment zone. Thermal sensors in the treatment zone monitor catheter temperature.
The EkoSonic System is intended for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature, according to the Bothell, Wash.-based company.
“Unlike mechanical devices, EKOS technology does not fracture the thrombus or damage red blood cells. Faster clot dissolution means a lower lytic drug dosage, resulting in fewer complications,” said Robert Hubert, EKOS president and CEO.